📰 Year Safety News
Year Safety News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Year Safety. Real-time updates on events, politics, business and more.
June 30, 2023
Continuous Kesimpta® treatment maintained profound suppression of MRI lesion activity and resulted in an increase in the number of patients with relapsing forms of...
April 28, 2023
More than 80% of relapsing MS patients who took Kesimpta continuously for five years in a trial did not have any worsening of disability.
April 20, 2023
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS)...
December 5, 2022
05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...
September 14, 2022
/PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE: SNN), the global medical technology company, today announces promising new data furthering a number of published...
September 8, 2022
An interim safety analysis from ECZTEND, an open-label, 5-year extension trial, demonstrated consistent safety from the parent trials for up to 3.5 years of Adbry (tralokinumab-ldrm) treatment in
April 12, 2022
Vikings Territory is the leading source of local/independent Minnesota Vikings news, opinion, analysis and content! New content daily!
March 25, 2022
Maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in... | March 25, 2022
March 25, 2022
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue